Apixaban for Extended Anticoagulation (APIDULCIS) — APIDULCIS  

Venous Thromboembolism Clinical Trial

Official title: APIDULCIS: Extended Anticoagulation With Low-dose Apixaban After a Standard Course Anticoagulation in Patients With a First Venous Thromboembolism Who Have Positive D-dimer

Status Terminated

Clinical Trial Summary

The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients at high risk of recurrence (with altered D-dimer test), who had received anticoagulation (whatever the drug used) for 12-15 months after the first episode of thrombosis, will be treated with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.

Clinical Trial Description

This prospective cohort study aims to assess the efficacy and safety of a management procedure to decide on giving or not an extended anticoagulation (administering apixaban 2 2.5 mg twice daily ) to outpatients with a single episode of proximal deep vein thrombosis of the lower limbs and/or pulmonary embolism who had received 12-15 months of anticoagulation (whatever the anticoagulant drug used). The study seeks to assess whether a management procedure involving D-dimer testing assessment can identify a subset of subjects at low risk of recurrence in whom an extended anticoagulation can be safely avoided. ;

Related Conditions & MeSH terms

• Anticoagulants
• Thromboembolism
• Venous Thromboembolism

• NCT number: NCT03678506
• Study type: Interventional
• Source: Arianna Anticoagulazione Foundation
• Status: Terminated
• Phase: Phase 4
• Start date: August 16, 2018
• Completion date: January 31, 2023